Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02126670 | ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis | PHASE2 | COMPLETED | 100 | — | — | Apr 1, 2014 | Sep 1, 2014 | Feb 22, 2016 | 4 | United States |
Treatment success at end of study visit defined as % of participants with 100% clearance of AK lesions
| Arm | Type | Description |
|---|---|---|
| ACT01 plus Comp01 | PLACEBO_COMPARATOR | ACT01 Cream in combination with Comp01 Cream, once daily, 29 days |
| ACT01 plus Comp02 | ACTIVE_COMPARATOR | ACT01 Cream in combination with Comp02 Cream, once daily, 29 days |
| ACT01 plus Comp03 | ACTIVE_COMPARATOR | ACT01 Cream in combination with Comp03 Cream, once daily, 29 days |
| ACT01 plus Comp04 | OTHER | ACT01 Cream in combination with Comp04 Cream, once daily, 29 days |
| Name | Type | Description |
|---|---|---|
| ACT01 | DRUG | - |
| Comp01 | DRUG | - |
| Comp02 | DRUG | - |
| Comp03 | DRUG | - |
| Comp04 | DRUG | - |
Inclusion Criteria: 1. Presence of actinic keratosis lesions on the face and/or scalp within a 25 cm2 contiguous area containing at least four lesions that are non-hypertrophic and non-hyperkeratotic and not larger than 6 mm in longest diameter. 2. Age 30-85 years, inclusive. 3. Good general health...